| Nasdaq: DYAX
Dyax Corp. is a biopharmaceutical company, which discovers, develops and commercializes biopharmaceuticals for unmet medical needs. The company utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development. It also develops angioedema portfolio for the prophylactic treatment of hereditary angioedema (HAE) and a diagnostic test to identify plasma kallikrein-mediated disorders. The company's business elements include Plasma Kallikrein-Mediated Angioedema Portfolio and Phage Display Licensing and Funded Research Program. It also develops KALBITOR for the treatment of acute attacks of HAE. Dyax was founded by Henry E. Blair and L. Edward Cannon in 1995 and is headquartered in Burlington, MA.